Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Nov 18, 2019
American Heart Association Scientific Sessions 2019

November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides”

November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”

Philadelphia
Nov 25, 2019 4:30 PM EST
Arrowhead Pharmaceuticals 2019 Year End Results
Archived Events
Date Event Details
May 15, 2019 8:40 AM PDT
Bank of America Merrill Lynch 2019 Health Care Conference
Las Vegas, Nevada
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation
May 15, 2019 11:00 AM EDT
Vascular Discovery: From Genes to Medicine 2019 Scientific Sessions (ATVB|PVD)
Boston

So Wong, Ph.D., Arrowhead’s director of biology, will deliver a poster presentation titled, “Reduction in Angiopoietin-Like Protein 3 via RNA Interference Improves Dyslipidemias and Hepatic Steatosis”

May 8, 2019 4:30 PM EDT
Arrowhead Pharmaceuticals 2019 Second Quarter Results
Apr 10, 2019
The EASL International Liver Congress 2019

Oral Presentation:
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold

  • Presentation Reference: PS-080
  • Session: Parallel session: Hepatitis B - drug development
  • Date and Time: April 12, 2019 at 5:45 p.m. CET
  • Authors: Man-Fung Yuen, et al.

Poster Presentation:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model

  • Presentation Reference: FRI-446
  • Session: Poster: Rare liver diseases (including pediatric and genetic)
  • Session Date and Time: April 12, 2019 from 9 a.m. to 5 p.m. CET
  • Authors: Christine Wooddell, et al.
Apr 3, 2019 8:00 AM EDT
AACR Annual Meeting 2019
So Wong, Ph.D., Arrowhead’s director of oncology, will deliver a poster presentation titled, “Optimizing the potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear cell renal cell carcinoma”
Mar 27 - Mar 30, 2019
CSHL Meeting: RNA & Oligonucleotide Therapeutics
Cold Spring Harbor, NY
Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular and lipid disorders - A next frontier for TRiMTM RNAi”
Mar 26, 2019 4:35 PM EDT
Oligonucleotide & Precision Therapeutics (OPT) Congress
Cambridge, MA
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “siRNA Clinical Development Based on the TRiMTM Platform”
Mar 18, 2019 9:30 AM EDT
Jefferies HBV Investor Summit
New York
Dr. Given will participate in a fireside chat presentation with Maury Raycroft, Ph.D., Jefferies Biotech Analyst
Mar 12, 2019 4:20 PM EDT
Barclays Global Healthcare Conference 2019
Miami
Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver a corporate presentation.
Feb 22, 2019
APASL 2019
Dr. Edward Gane will deliver a poster presentation titled, “RNA interference (RNAi) in chronic hepatitis B (CHB): Data from Phase 2 study with JNJ-3989”